Monthly Archives: April 2016

Deal Alert! Gluten Free and More Magazine 70% Off Sale Today Only!

glutenfreeandmore-spring-2016Hey Friend!

I have to share a super opportunity to get a fantastic gluten-free magazine at an AWESOME deal! Gluten Free & More is an excellent magazine with tons of recipes, tips and features that will help you live the gluten-free lifestyle.

Today ONLY, you can get Gluten Free & More for 70% off the regular price!

I just found out about this great deal in an email I received from Alicia Woodward, Gluten-Free & More’s editor-in-chief….

Right now, for 24 hours only, you can get a years-worth of Gluten Free & More for 70%-OFF our cover price. That’s a year-long print subscription for just $14.95. And it’s only available for 24 hours, so subscribe today!

Why the amazing deal? Because it’s the best way I know to introduce you to the TONS of amazing, easy-to-make recipes, inspiration, and information you’ll find in each issue.

You’ll love all the delicious recipes for dishes like double-chocolate cake, delicious gluten-free breads, and plenty of gluten-free comfort foods.
Try Gluten Free & More today to take advantage of this limited-time offer. Don’t miss out, subscribe now.

Sincerely,

Alicia Woodward

Editor-in-Chief
Gluten Free & More

P.S. Don’t miss your chance to take advantage of our amazing limited-time offer…subscribe and save 70% today!

Get your incredibly discounted Gluten Free & More subscription by Clicking Here! The deal only lasts 24 hours so Hurry and get yours now!

Warm regards,

John

John Libonati

Glutenfreeworks.com

ImmunogenX Acquires Celiac Disease Therapy from Alvine Pharmaceuticals

Immunogenx-logo-lowx41[1]A therapy for celiac disease is one step closer. ImmunogenX purchased the license for Alvine Pharmaceuticals’ medicine, ALV003, which degrades gluten before it can be digested and absorbed by the intestines. The following press release was distributed by ImmunogenX.

“Glutenase for in-vivo gluten degradation is a leading candidate for celiac disease ImmunogenX™, a biopharmaceutical company focused on the diagnosis and treatment of autoimmune and gastrointestinal diseases, today announced that it has completed the acquisition of the non-cash assets of Alvine Pharmaceuticals.

This includes Latiglutenase (formerly known as ALV003 and renamed IMGX003), an orally administered mixture of two recombinant gluten-specific proteases that degrades gluten proteins into small physiologically irrelevant fragments. The technology is backed by over 50 issued or pending patents, has been extensively studied in Phase I and Phase 2 clinical trials, and is the only CD treatment that has demonstrated histologic success as well as symptomatic improvements in Read More »

>